Sciele acquisition and Crestor shore up Shionogi's top line
This article was originally published in Scrip
Shionogi's net sales of ¥278.5 billion ($2.98 billion) in the fiscal year to 31 March marked a jump of 22% from the previous 12 months, helped by the contribution of Sciele Pharma (now Shionogi USA), which added ¥38.6 billion to the top line figure.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.